New Hope for Bladder Cancer: Enfortumab Vedotin and Pembrolizumab Combination Shows Promise
A groundbreaking study presented at the 2026 ASCO Genitourinary Cancers Symposium is reshaping the treatment landscape for muscle-invasive bladder cancer (MIBC). The KEYNOTE-B15/EV-304 trial demonstrates that a combination of enfortumab vedotin and pembrolizumab, administered both before and after surgery, significantly improves outcomes for patients eligible for cisplatin-based chemotherapy.
The Challenge of Muscle-Invasive Bladder Cancer
For decades, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been the standard approach for MIBC. However, nearly half of patients still experience metastatic recurrence, highlighting the urgent need for more effective perioperative strategies. This new research offers a potential solution.
KEYNOTE-B15/EV-304: A Game-Changing Trial
The phase III KEYNOTE-B15 trial enrolled 808 patients with MIBC. Participants were randomized to receive either neoadjuvant enfortumab vedotin plus pembrolizumab or standard gemcitabine and cisplatin chemotherapy before undergoing cystectomy. The study focused on event-free survival (EFS) as its primary endpoint, with overall survival (OS) and pathologic complete response (pCR) rates as key secondary endpoints.
Significant Improvements Across Key Metrics
The results were compelling. Median event-free survival was not reached in the enfortumab vedotin plus pembrolizumab group, compared to 48.5 months in the chemotherapy group (HR 0.53, 95% CI 0.41–0.70). At 24 months, EFS rates were 79.4% versus 66.2%, respectively. Overall survival also showed improvement, with 24-month rates of 86.9% and 81.3% (HR = 0.65, 95% CI = 0.48–0.89). The pathologic complete response rate was significantly higher with the combination therapy (55.8% vs 32.5%).
Understanding the Drug Combination
Enfortumab vedotin is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein often found on bladder cancer cells. Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. Combining these two approaches appears to create a synergistic effect, leading to improved outcomes.
Safety Considerations
Grade ≥ 3 treatment-emergent adverse events occurred in 75.7% of patients receiving enfortumab vedotin plus pembrolizumab and 67.2% of those receiving chemotherapy. Common adverse events of special interest included skin reactions with enfortumab vedotin and severe skin reactions with pembrolizumab. These findings suggest careful monitoring and management of side effects are crucial.
Expert Perspective: A Potential New Standard of Care
“Muscle-invasive bladder cancer can be difficult to treat, and conventional treatments often fall short of preventing metastatic recurrence,” stated Wm. Kevin Kelly, DO, FASCO, an ASCO Expert in genitourinary oncology. “The KEYNOTE-B15 study marks an exciting development in establishing a potential new treatment option and standard of care for these patients.”
Future Trends and Implications
The success of KEYNOTE-B15/EV-304 is likely to spur further research and development in several key areas:
Expanding Combination Therapies
Researchers will likely explore combining enfortumab vedotin and pembrolizumab with other therapies, such as novel chemotherapeutic agents or other immunotherapies, to further enhance treatment efficacy. The goal is to identify the optimal combination for different patient subgroups.
Biomarker-Driven Approaches
Identifying biomarkers that predict response to enfortumab vedotin and pembrolizumab will be crucial for personalizing treatment. This could involve analyzing tumor characteristics, immune profiles, or genetic factors to determine which patients are most likely to benefit from this combination.
Addressing Treatment Resistance
Understanding the mechanisms of resistance to enfortumab vedotin and pembrolizumab will be essential for developing strategies to overcome resistance and maintain treatment efficacy over time. This may involve identifying alternative targets or developing new drugs that circumvent resistance mechanisms.
Optimizing Treatment Sequencing
Further research is needed to determine the optimal sequencing of enfortumab vedotin and pembrolizumab with other therapies, such as chemotherapy or radiation therapy. This could involve exploring different treatment schedules or combining therapies in different orders to maximize efficacy and minimize toxicity.
Frequently Asked Questions
Q: What is muscle-invasive bladder cancer?
A: MIBC is a type of bladder cancer that has grown into the muscle layer of the bladder wall. It is a more aggressive form of bladder cancer than non-muscle-invasive bladder cancer.
Q: What are the potential side effects of enfortumab vedotin and pembrolizumab?
A: Common side effects include skin reactions, fatigue, and nausea. More serious side effects can occur, so it’s important to discuss potential risks with your doctor.
Q: Is this treatment option available to all bladder cancer patients?
A: This treatment is currently indicated for patients with MIBC who are eligible for cisplatin-based chemotherapy.
Q: What is neoadjuvant and adjuvant treatment?
A: Neoadjuvant treatment is given before surgery, while adjuvant treatment is given after surgery.
Did you know? The KEYNOTE-B15 trial is the first to demonstrate a significant improvement in overall survival with a perioperative treatment regimen for MIBC.
Pro Tip: Discuss all treatment options with your oncologist to determine the best course of action for your individual situation.
Stay informed about the latest advancements in bladder cancer treatment. Explore additional resources on the American Cancer Society website and consult with your healthcare provider for personalized guidance.
